A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Latest Information Update: 23 Sep 2022
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Pembrolizumab
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms IMspire170
- Sponsors Genentech; Roche
- 24 Aug 2022 Status changed from completed to discontinued due to benefit/risk analysis.
- 02 Jun 2021 Status changed from active, no longer recruiting to completed.
- 09 Apr 2021 This trial has been completed in Poland (Global End Date: 19 Feb 2021), according to European Clinical Trials Database record.